| Application number | Title of the application | Filing Date | Status |
|---|
| 09/336414 | MODULATING PLATELET FUNCTION | Jun 17, 1999 | Abandoned |
| 09/335088 | ANTI-TUMOR AGENT COMPRISING SALMOSIN AS AN ACTIVE INGREDIENT | Jun 16, 1999 | Abandoned |
Array
(
[id] => 4320326
[patent_doc_number] => 06328968
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2001-12-11
[patent_title] => 'Methods and means for modifying complement activation'
[patent_app_type] => 1
[patent_app_number] => 9/242161
[patent_app_country] => US
[patent_app_date] => 1999-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 4617
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/328/06328968.pdf
[firstpage_image] =>[orig_patent_app_number] => 242161
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/242161 | Methods and means for modifying complement activation | Jun 10, 1999 | Issued |
Array
(
[id] => 1459898
[patent_doc_number] => 06391855
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-05-21
[patent_title] => 'Compounds and methods for modulating junctional adhesion molecule-mediated functions'
[patent_app_type] => B1
[patent_app_number] => 09/324541
[patent_app_country] => US
[patent_app_date] => 1999-06-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 22326
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/391/06391855.pdf
[firstpage_image] =>[orig_patent_app_number] => 09324541
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/324541 | Compounds and methods for modulating junctional adhesion molecule-mediated functions | Jun 1, 1999 | Issued |
Array
(
[id] => 1391969
[patent_doc_number] => 06531129
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2003-03-11
[patent_title] => 'Heparanase specific molecular probes and their use in research and medical applications'
[patent_app_type] => B2
[patent_app_number] => 09/322977
[patent_app_country] => US
[patent_app_date] => 1999-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 56
[patent_no_of_words] => 16834
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 114
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/531/06531129.pdf
[firstpage_image] =>[orig_patent_app_number] => 09322977
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/322977 | Heparanase specific molecular probes and their use in research and medical applications | May 31, 1999 | Issued |
Array
(
[id] => 1467215
[patent_doc_number] => 06458767
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-10-01
[patent_title] => 'Use of peptides inhibitory for thrombospondin dependent TGF- activation in the treatment of kidney disease'
[patent_app_type] => B1
[patent_app_number] => 09/321932
[patent_app_country] => US
[patent_app_date] => 1999-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 18
[patent_no_of_words] => 12349
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/458/06458767.pdf
[firstpage_image] =>[orig_patent_app_number] => 09321932
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/321932 | Use of peptides inhibitory for thrombospondin dependent TGF- activation in the treatment of kidney disease | May 27, 1999 | Issued |
Array
(
[id] => 1315936
[patent_doc_number] => 06608030
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2003-08-19
[patent_title] => 'Suppression of immune response via inhibition of cathepsin S'
[patent_app_type] => B1
[patent_app_number] => 09/155956
[patent_app_country] => US
[patent_app_date] => 1999-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12654
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/608/06608030.pdf
[firstpage_image] =>[orig_patent_app_number] => 09155956
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/155956 | Suppression of immune response via inhibition of cathepsin S | May 18, 1999 | Issued |
Array
(
[id] => 4333321
[patent_doc_number] => 06333035
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2001-12-25
[patent_title] => 'Medicinal composition containing gp34 binding-inhibitor as the active ingredient'
[patent_app_type] => 1
[patent_app_number] => 9/308332
[patent_app_country] => US
[patent_app_date] => 1999-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 4507
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/333/06333035.pdf
[firstpage_image] =>[orig_patent_app_number] => 308332
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/308332 | Medicinal composition containing gp34 binding-inhibitor as the active ingredient | May 18, 1999 | Issued |
Array
(
[id] => 1548537
[patent_doc_number] => 06346243
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-02-12
[patent_title] => 'Inhibition of transplant rejection by type one interferon'
[patent_app_type] => B1
[patent_app_number] => 09/314503
[patent_app_country] => US
[patent_app_date] => 1999-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 6
[patent_no_of_words] => 7540
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/346/06346243.pdf
[firstpage_image] =>[orig_patent_app_number] => 09314503
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/314503 | Inhibition of transplant rejection by type one interferon | May 18, 1999 | Issued |
| 09/305688 | METHODS AND COMPOSITIONS FOR DECREASING MITOCHONDRIAL OVERPRODUCTION OF REACTIVE OXYGEN SPECIES IN CELLS | May 3, 1999 | Abandoned |
Array
(
[id] => 4134367
[patent_doc_number] => 06034230
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2000-03-07
[patent_title] => 'Nucleic acids encoding myocardial peptides'
[patent_app_type] => 1
[patent_app_number] => 9/303862
[patent_app_country] => US
[patent_app_date] => 1999-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12254
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/034/06034230.pdf
[firstpage_image] =>[orig_patent_app_number] => 303862
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/303862 | Nucleic acids encoding myocardial peptides | May 2, 1999 | Issued |
| 09/304006 | COMPOSITION AND METHOD FOR ENHANCING IMMUNOLOGICAL MEMORY RESPONSE | Apr 29, 1999 | Abandoned |
| 09/303161 | CELL STRESS REGULATED HUMAN MHC CLASS I GENE | Apr 28, 1999 | Abandoned |
Array
(
[id] => 4290341
[patent_doc_number] => 06268485
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2001-07-31
[patent_title] => 'Down-regulation resistant C3 convertase'
[patent_app_type] => 1
[patent_app_number] => 9/142334
[patent_app_country] => US
[patent_app_date] => 1999-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 24835
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 191
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/268/06268485.pdf
[firstpage_image] =>[orig_patent_app_number] => 142334
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/142334 | Down-regulation resistant C3 convertase | Apr 14, 1999 | Issued |
| 09/293504 | T CELL INHIBITORY RECEPTOR COMPOSITIONS AND USES THEREOF | Apr 14, 1999 | Abandoned |
Array
(
[id] => 4240588
[patent_doc_number] => 06136312
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2000-10-24
[patent_title] => 'Method for producing an IgM preparation for intravenous application'
[patent_app_type] => 1
[patent_app_number] => 9/269746
[patent_app_country] => US
[patent_app_date] => 1999-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 1817
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/136/06136312.pdf
[firstpage_image] =>[orig_patent_app_number] => 269746
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/269746 | Method for producing an IgM preparation for intravenous application | Apr 6, 1999 | Issued |
| 09/285477 | LFA-1 REGULATORY BINDING SITE AND USES THEREOF | Apr 1, 1999 | Abandoned |
Array
(
[id] => 4112628
[patent_doc_number] => 06071516
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2000-06-06
[patent_title] => 'Treatment of Post-Polio Syndrome with gamma-globulin'
[patent_app_type] => 1
[patent_app_number] => 9/285125
[patent_app_country] => US
[patent_app_date] => 1999-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3305
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/071/06071516.pdf
[firstpage_image] =>[orig_patent_app_number] => 285125
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/285125 | Treatment of Post-Polio Syndrome with gamma-globulin | Mar 31, 1999 | Issued |
| 09/269779 | PHARMACEUTICAL PRODUCTS CONTAINING PROTEIN-TYROSINE KINASE INHIBITORS AND ANTI-CD4 ANTIBODIES | Mar 30, 1999 | Abandoned |
Array
(
[id] => 4273921
[patent_doc_number] => 06245890
[patent_country] => US
[patent_kind] => NA
[patent_issue_date] => 2001-06-12
[patent_title] => 'Porcine protein and uses thereof'
[patent_app_type] => 1
[patent_app_number] => 9/277391
[patent_app_country] => US
[patent_app_date] => 1999-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 14
[patent_no_of_words] => 9579
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/245/06245890.pdf
[firstpage_image] =>[orig_patent_app_number] => 277391
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/277391 | Porcine protein and uses thereof | Mar 25, 1999 | Issued |
